Bluebird bio Inc
NASDAQ:BLUE 11:06:03 AM EDT
| Market Cap (Intraday) | 709.51M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $10.77 |
| 50-Day MA | $11.93 |
| 200-Day MA | $15.33 |
Bluebird bio Inc Stock, NASDAQ:BLUE
60 Binney Street, 60 Binney Street, Cambridge, Massachusetts 02142
United States of America
Phone: +1.339.499.9300
Number of Employees: 1213
Description
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.